Cargando…

Pramipexole Extended Release: A Novel Treatment Option in Parkinson's Disease

Pramipexole, the most commonly prescribed dopamine agonist worldwide, meanwhile serves as a reference substance for evaluation of new drugs. Based on numerous clinical data and vast experiences, efficacy and safety profiles of this non-ergoline dopamine agonist are well characterized. Since October...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eisenreich, Wolfram, Sommer, Bernd, Hartter, Sebastian, Jost, Wolfgang H.
Formato:	Texto
Lenguaje:	English
Publicado:	SAGE-Hindawi Access to Research 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010659/ https://www.ncbi.nlm.nih.gov/pubmed/21209705 http://dx.doi.org/10.4061/2010/612619

Ejemplares similares

Pramipexole and its Extended Release Formulation for Parkinson’s Disease
por: Fishman, Paul S.
Publicado: (2011)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease
por: Hametner, Eva-Maria, et al.
Publicado: (2012)

P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease
por: Hauser, Robert A., et al.
Publicado: (2022)

Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole
por: Salawu, Fatai Kunle
Publicado: (2012)

Auditory Musical Hallucinations Associated With Extended-Release Pramipexole in an Elderly Patient With Parkinson's Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2014)

Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
por: Hauser, Robert A., et al.
Publicado: (2014)

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease
por: Hauser, R A, et al.
Publicado: (2014)

The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients
por: Faddoul, Lama, et al.
Publicado: (2018)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease
por: Shen, Zhengze, et al.
Publicado: (2018)

Update on the use of pramipexole in the treatment of Parkinson’s disease
por: Constantinescu, Radu
Publicado: (2008)

Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease
por: Piedad, John C. P., et al.
Publicado: (2012)

Analysis of pramipexole dose–response relationships in Parkinson’s disease
por: Wang, Ying, et al.
Publicado: (2016)

Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease
por: Sun, Yongqi, et al.
Publicado: (2022)

Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Dopamine Dysregulation Syndrome in Parkinson’s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?
por: Solla, Paolo, et al.
Publicado: (2013)

Changes in Pramipexole Utilization after Introduction of the Extended-Release Formulation: A Nationwide Study in Taiwan
por: Chan, K. Arnold, et al.
Publicado: (2020)

Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease
por: Kano, Osamu, et al.
Publicado: (2008)

Retracted: Pramipexole Inhibits Neuronal Apoptosis in Rats with Parkinson's Disease
por: Healthcare Engineering, Journal of
Publicado: (2023)

Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations
por: Xiang, Wei, et al.
Publicado: (2018)

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
por: Antonini, Angelo, et al.
Publicado: (2011)

Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson's disease patients
por: Luo, He-Ting, et al.
Publicado: (2016)

Possible effects of pramipexole on neck muscles in a patient with Parkinson's disease
por: Filippi, Roberto, et al.
Publicado: (2014)

Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease: A randomized parallel-group trial
por: Ziaei, Ehsan, et al.
Publicado: (2022)

Pramipexole-induced antecollis in patients with Parkinson's disease: Two cases and literature review
por: Iijima, Mutsumi, et al.
Publicado: (2015)

Pramipexole: new use for an old drug – the potential use of pramipexole in the treatment of restless legs syndrome
por: Benbir, Gulcin, et al.
Publicado: (2006)

Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study
por: Zhou, Haiyan, et al.
Publicado: (2021)

Efficacy of pramipexole combined with levodopa for Parkinson’s disease treatment and their effects on QOL and serum TNF-α levels
por: Huang, Jinzhong, et al.
Publicado: (2020)

Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson’s Disease
por: Choi, Yoonjae, et al.
Publicado: (2010)

Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson’s Disease
por: Choi, Yoonjae, et al.
Publicado: (2011)

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
por: Schapira, Anthony HV, et al.
Publicado: (2013)

Retraction: Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Pramipexole in a Patient with Parkinson’s Disease
Publicado: (2015)

Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients
por: Deutschländer, Angela, et al.
Publicado: (2016)

Efficacy of pramipexole on quality of life in patients with Parkinson’s disease: a systematic review and meta-analysis
por: Li, Tao, et al.
Publicado: (2022)

Dramatic Response to Pramipexole in Delayed-Onset Parkinsonism from Osmotic Demyelinating Syndrome
por: Han, Steve C., et al.
Publicado: (2020)

Pramipexole use and the risk of pneumonia
por: Ernst, Pierre, et al.
Publicado: (2012)

CircSNCA downregulation by pramipexole treatment mediates cell apoptosis and autophagy in Parkinson’s disease by targeting miR-7
por: Sang, Qiuling, et al.
Publicado: (2018)

Nondipping in Parkinson's Disease
por: Sommer, Sita, et al.
Publicado: (2011)

Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
por: Huss, Michael, et al.
Publicado: (2015)

Burning mouth syndrome responsive to pramipexol
por: Stuginski-Barbosa, J., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_acqab82ralvi248koiehm741ii